Dr. Benjamin Petsch, Senior Director Infectious Disease Research at CureVac AG. His responsibility is the pre-clinical research and development of mRNA-based prophylactic vaccines using CureVac’s RNActive technology. He received his university degree in biology from University of Munich and performed his doctoral thesis on the generation of monoclonal antibodies at the Institute of Immunology of the Friedrich-Loeffler-Institut, Tuebingen, where he continued as a postdoc and then as a research group leader working on mRNA vaccination against Influenza and on intervention of Influenza replication using small molecules. He joined CureVac in 2010 as a scientist in the department of Vaccines developing mRNA based vaccines against infectious diseases and is leading this department since 2013. Dr. Petsch performed the ADVAC training in 2018 and is inventor on several patent applications on mRNA based vaccination and author of several scientific articles on infectious disease research.